Multiple primary tumors does not change survival rates in melanoma patients

This study compared survival rates between melanoma patients with multiple primary melanoma (MPM) and single primary melanoma (SPM). Researchers suggested that MPM and SPM patients have similar survival rates.

An estimated 87,110 Americans were diagnosed with advanced melanoma in 2017. New melanoma cases are projected to continue to increase at a rate of 3% annually. Prior studies suggested that SPM patients have a longer survival rate when compared to MPM patients. However, other studies suggested that SPM survival is shorter or even similar than MPM patients. Survival studies are necessary to accurately predict prognosis and better treat the patients.

This study included records of 14,138 melanoma patients. This included 887 MPM patients (with 2 or more primary melanomas). 887 matched SPM patients were chosen for comparison. These patients were followed up for 173.9 months and survival rates were assessed.

No survival difference was observed between MPM and SPM patients. There was no significant difference in survival in patients with invasive melanomas (melanomas that have traveled deeper into the skin or to other areas).

This study determined that there is no difference in survival rates between SPM and MPM patients.